[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338674-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338674-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","how-long-do-i-have-examining-survival-outcomes-in-laryngeal-cancer-patients-managed-with-non-curative-intent-in-northern-uk-insights-from-the-northern-head-neck-cancer-alliance-retrospective-study","‘How Long Do I Have?’ - Examining survival outcomes in laryngeal cancer patients managed with non-curative intent in Northern UK - Insights from the Northern Head & Neck Cancer Alliance Retrospective Study","","How Long Do I Have? examines survival outcomes for laryngeal cancer patients managed with non-curative intent in Northern UK. Historically, 15% of patients receive non-curative management, yet pragmatic data remain limited, making survival estimates important for shared decision-making. A retrospective multicentre study collected demographic information, treatment details, tumour stage, anatomical subsite, and clinical outcomes across five tertiary head and neck centres.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/how-long-do-i-have-examining-survival-outcomes-in-laryngeal-cancer-patients-managed-with-non-curative-intent-in-northern-uk-insights-from-the-northern-head-neck-cancer-alliance-retrospective-study/338674/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/how-long-do-i-have-examining-survival-outcomes-in-laryngeal-cancer-patients-managed-with-non-curative-intent-in-northern-uk-insights-from-the-northern-head-neck-cancer-alliance-retrospective-study/338674.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What patient population was studied in this research?","Question",{"text":63,"@type":64},"Patients with laryngeal squamous cell cancer managed with non-curative intent were included, drawn from five large tertiary head and neck centres in Northern UK.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What survival outcomes were reported for the cohort?",{"text":68,"@type":64},"Among 373 patients, the mean survival time (MST) was 9.1 months, with differences by metastatic status, tumour stage, and anatomical subsite.",{"name":70,"@type":61,"acceptedAnswer":71},"How do results differ between early-stage and advanced disease?",{"text":72,"@type":64},"Early-stage patients had an MST of 13.3 months, compared with 8.2 months for advanced disease.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338674,1790333972,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Clinical Otolaryngology  \nORIGINAL ARTICLE  OPEN ACCESS   \n‘How Long Do I Have?’ – Examining survival outcomesin laryngeal cancer patients managed with non-curative intent in Northern UK: Insights from the Northern Head & Neck Cancer Alliance Retrospective Study  \nAmarkumar Rajgor1,2 | Rhona Hurley3,4,5  | Catriona M. Douglas3,4,5 | Claire Paterson3,4,5  | James Moor6  | Shane Lester7 | Sara Sionis8 | Katharine Davies9 | James O'Hara2 | Gareth Inman3,4,5 | Terry Jones9,10 |  \nDavid Winston Hamilton2 | Northern Head & Neck Alliance  \n1National Institute for Health & Care Research Doctoral Fellow in Otolaryngology, Population Health Sciences Institute, Newcastle University, NewcastleUpon-Tyne, UK | 2Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle-Upon-Tyne, UK | 3NHS Greater Glasgow & Clyde, Newcastle-Upon-Tyne, UK | 4Glasgow Head and Neck Research (GLAHNC) Group, Glasgow, UK | 5CRUK Scotland Institute and School of Cancer Sciences, College of Medical and Veterinary Sciences, University of Glasgow, Glasgow, UK | 6Leeds Teaching Hospitals NHS Foundation Trust, Leeds, UK | 7South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK | 8Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield,  \nUK | 9Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK | 10Liverpool Head & Neck Centre, Liverpool, UK Correspondence: Amarkumar Rajgor ([amar.rajgor@newcastle.ac.uk](amar.rajgor@newcastle.ac.uk))  \nReceived: 6 September 2024 | Accepted: 8 November 2024  \nFunding: There were no specific grants from any funding agency, commercial or not-for-profit sectors. Of note, AR is currently a National Institute for Health and Care Research (NIHR) Doctoral Fellow (Grant NIHR302984) . The views expressed in this publication are those of the authors and not necessarily those of the NIHR. RH is supported by a Cancer Research UK funded clinical academic training program (TRACC) PhD studentship and Cancer Research UK award to GI (A29802) .  \nKeywords: Laryngeal cancer | Multidisciplinary approach | Palliative care | Survival outcomes  \nABSTRACT  \nIntroduction: Historically, 15% of laryngeal cancer patients undergo non-curative management, but pragmatic data on this group are limited. This information is crucial to help patients make informed decisions about their care. Supported by the Northern Head & Neck Alliance, this retrospective study is the first to present survival outcomes for non-curative laryngeal cancer patients in Northern UK.  \nMethods: Retrospective data were compiled for patients with laryngeal squamous cell cancer from five large tertiary head and neck centres in Northern UK (Newcastle, Glasgow, Sheffield, Leeds, and Middlesbrough) . The collected data encompassed demographic details, treatment and clinical outcomes.  \nResults: Among 373 patients, the mean age was 72, and 73% were male. The median follow-up was 6 months. 17% had earlystage (T1-2), and 83% had late-stage (T3-4) disease. By data collection, 99% had died.  \nThe mean survival time (MST) was 9.1 months. Patients with metastases had an MST of 6.9 months, while those without had 9.4 months. Early-stage patients had an MST of 13.3 months, compared to 8.2 months for advanced disease. By subsite, MSTs were 8.2 months for supraglottic, 12.5 for glottic, 5.5 for subglottic, and 7.9 for transglottic cancers.  \nConclusion: This study stands as the first to explore survival outcomes in laryngeal cancer patients undergoing non-curative management. The findings can provide valuable insights for informing patients about survival in the absence of radical treatment, facilitating important decision-making conversations.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2024 The Author(s). Clinical Otolaryngology published by John Wiley & Sons Ltd.  \n344 Clinical Otolaryngology, 2025; ","cbCaiaNAgs99krv6","https://ap.wps.com/l/cbCaiaNAgs99krv6","pdf",1139927,"English","# Introduction\n## Study background and rationale\n# Methods\n## Retrospective data collection\n# Results\n## Patient characteristics and survival metrics\n# Conclusion\n## Clinical implications for decision-making","[{\"question\":\"What patient population was studied in this research?\",\"answer\":\"Patients with laryngeal squamous cell cancer managed with non-curative intent were included, drawn from five large tertiary head and neck centres in Northern UK.\"},{\"question\":\"What survival outcomes were reported for the cohort?\",\"answer\":\"Among 373 patients, the mean survival time (MST) was 9.1 months, with differences by metastatic status, tumour stage, and anatomical subsite.\"},{\"question\":\"How do results differ between early-stage and advanced disease?\",\"answer\":\"Early-stage patients had an MST of 13.3 months, compared with 8.2 months for advanced disease.\"}]","‘How Long Do I Have?’ - Examining survival outcomes in laryngeal cancer patients managed with non-curative intent in Northern UK - Insights from the Northern Head & Neck Cancer Alliance Retrospective Study | PDF",1790024967,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/378dbf3923d2daf45bbeca4b22f502be.webp",983,1291,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00753f1e007244d8f4eb61bde299835d.webp",982,1290,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30c3f6c29cb96992b537bb7b15514e6a.webp",981,1289,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9be886bde178a34ea39894e7a4dc7702.webp",980,1287]